title: [Nasal cavity and paranasal sinus malignancies in the ENT clinic of Charité since 1959].
abstract: A retrospective analysis of 235 cases suffering from nasal and/or paranasal sinus malignant tumours who were admitted to the Charité ENT-Clinic between 1959 and 1989, is presented. 94 of the patients were women and 141 men, the mean age being 63.8 years (women) and 61.8 years (men), respectively. The most common histomorphological diagnosis was carcinoma (66%), followed by lymphoma/sarcoma (17%). 35% of all tumours originated in the nasal cavity, 38% in the maxillary sinus, 22% in the ethmoidal sinuses. At the time of admission many tumours had already invaded surrounding structures. Tumour invasion of the pterygopalatine fossa was noted in 52 patients, invasion of the orbit in 89 and of the skull base in 65 cases. Our therapy mainly depended on the histology of the tumours. 19% of all carcinomas were treated by surgery only, in 48% surgery and postoperative radiation was the therapy of choice. 59% of lymphomas/sarcomas were treated by radiation only. 100 out of these 227 patients treated because of sinus malignancy developed recurrencies. The 5-year survival rate was 30% in general, 29% for the years 1959-1970, 31% for the years 1971-1984 and for the T1 to T4 type cancers 54%, 38%, 19% and 19%, respectively.
authors.affiliation: Medizinische Fakultät (Charité) der Humboldt-Universität zu Berlin.
authors.forename: B
authors.initials: B
authors.lastname: Ströhmann
authors.forename: K
authors.initials: K
authors.lastname: Haake
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001604:Berlin / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009669:Nose Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010255:Paranasal Sinus Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies
vernacular_title: Nasenhöhlen- und Nasennebenhöhlen-Malignome an der HNO-Klinik der Charité seit 1959.